Pictet Asset Management Holding SA Cuts Stock Position in Kymera Therapeutics, Inc. $KYMR

Pictet Asset Management Holding SA cut its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 3.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 468,728 shares of the company’s stock after selling 14,471 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Kymera Therapeutics were worth $38,760,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Smartleaf Asset Management LLC lifted its position in Kymera Therapeutics by 382.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after buying an additional 424 shares during the last quarter. Larson Financial Group LLC grew its position in Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after acquiring an additional 349 shares during the last quarter. Osaic Holdings Inc. raised its stake in shares of Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after acquiring an additional 1,083 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of Kymera Therapeutics during the fourth quarter worth approximately $63,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Kymera Therapeutics in the 2nd quarter worth approximately $73,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Bank of America upped their price objective on shares of Kymera Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a research note on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Tuesday, April 21st. UBS Group boosted their price target on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a research note on Tuesday, March 3rd. Truist Financial upped their price target on shares of Kymera Therapeutics from $116.00 to $136.00 and gave the company a “buy” rating in a research report on Monday. Finally, B. Riley Financial raised their price objective on Kymera Therapeutics from $117.00 to $155.00 and gave the company a “buy” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Kymera Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $121.41.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR opened at $114.67 on Wednesday. The firm has a market cap of $9.43 billion, a PE ratio of -32.12 and a beta of 2.02. Kymera Therapeutics, Inc. has a fifty-two week low of $36.65 and a fifty-two week high of $130.05. The business has a 50 day moving average price of $85.81 and a 200-day moving average price of $82.55.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The firm had revenue of $34.37 million for the quarter, compared to analysts’ expectations of $8.27 million. During the same quarter last year, the business earned ($0.82) earnings per share. The business’s revenue was up 55.5% on a year-over-year basis. Research analysts predict that Kymera Therapeutics, Inc. will post -3.28 EPS for the current year.

Insider Buying and Selling at Kymera Therapeutics

In other news, insider Noah Goodman sold 5,000 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $114.00, for a total transaction of $570,000.00. Following the completion of the transaction, the insider directly owned 50,195 shares of the company’s stock, valued at approximately $5,722,230. This represents a 9.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Bvf Partners L. P/Il sold 1,578,800 shares of the stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $106.50, for a total transaction of $168,142,200.00. Following the sale, the director owned 240,123 shares of the company’s stock, valued at approximately $25,573,099.50. This represents a 86.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 3,461,271 shares of company stock valued at $368,858,355 in the last quarter. Company insiders own 15.98% of the company’s stock.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.